ODTC
Odonate Therapeutics, Inc. [ODTC] Stock Forecast
Buy or Sell ? Support and Resistance
What is MACD and how to read it?
How RSI can help?
RSI : 000
ODTC Stock Summary
In the News
ODTC Financial details
Company Rating
Neutral
Market Cap
34.64K
Income
-112.49M
Revenue
0
Book val./share
1.88
Cash/share
2.51
Dividend
-
Dividend %
-
Employees
137
Optionable
No
Shortable
Yes
Earnings
08 Nov 2022
P/E
-0.47
Forward P/E
-
PEG
0.1
P/S
-
P/B
0.43
P/C
0.6
P/FCF
-
Quick Ratio
5.81
Current Ratio
5.91
Debt / Equity
0.07
LT Debt / Equity
0.06
-
-
EPS (TTM)
-2.12
EPS next Y
-
EPS next Q
-
EPS this Y
-2.54%
EPS next Y
-
EPS next 5Y
-
EPS last 5Y
-
Revenue last 5Y
-
Revenue Q/Q
-
EPS Q/Q
6.78%
-
-
-
-
SMA20
-99.55%
SMA50
-99.85%
SMA100
-6.83%
Inst Own
14.26%
Inst Trans
0.22%
ROA
-75%
ROE
-85%
ROC
-0.9%
Gross Margin
-
Oper. Margin
-
Profit Margin
-
Payout
-
Shs Outstand
19.25K
Shs Float
17.57K
-
-
-
-
Target Price
-
52W Range
1.5-2.42
52W High
-25%
52W Low
+50%
RSI
48.11
Rel Volume
-
Avg Volume
2.63K
Volume
Perf Week
0%
Perf Month
0%
Perf Quarter
-12.79%
Perf Half Y
-16.67%
-
-
-
-
Beta
0.027662
-
-
Volatility
0%, 747.96%
Prev Close
0%
Price
1.5
Change
0%
ODTC Financial Performance
Yearly Fundamentals Overview
Last date of statement is 2020-12-31
| Metric | History | 2016-12-31 | 2017-12-31 | 2018-12-31 | 2019-12-31 | 2020-12-31 |
|---|---|---|---|---|---|---|
| 2.02K | 2.02K | 2.02K | 2.02K | 2.02K | ||
| Revenue per share | 0 | 0 | 0 | 0 | 0 | |
| Net income per share | -0.11 | -2.31 | -3.64 | -3.94 | -3.84 | |
| Operating cash flow per share | -0.06 | -1.82 | -2.74 | -3.5 | -3.44 | |
| Free cash flow per share | -0.06 | -1.83 | -2.82 | -3.5 | -3.46 | |
| Cash per share | 0.1 | 13.98 | 5.68 | 6.53 | 4.79 | |
| Book value per share | 0.08 | 13.83 | 5.07 | 5.88 | 4.14 | |
| Tangible book value per share | 0.08 | 13.83 | 5.07 | 5.88 | 4.14 | |
| Share holders equity per share | 0.08 | 13.83 | 5.07 | 5.88 | 4.14 | |
| Interest debt per share | 0 | 0 | 0 | 0.07 | 0.16 | |
| Market cap | 1236.96B | 708.47B | 688.86B | 1792.89B | 1261.92B | |
| Enterprise value | 1236.95B | 708.28B | 688.72B | 1792.71B | 1261.77B | |
| P/E ratio | -400.96K | -21.64K | -7.74K | -16.49K | -9.99K | |
| Price to sales ratio | 0 | 0 | 0 | 0 | 0 | |
| POCF ratio | -713.77K | -27.4K | -10.27K | -18.55K | -11.15K | |
| PFCF ratio | -713.77K | -27.31K | -9.98K | -18.52K | -11.11K | |
| P/B Ratio | 541.81K | 3.61K | 5.56K | 11.05K | 9.27K | |
| PTB ratio | 541.81K | 3.61K | 5.56K | 11.05K | 9.27K | |
| EV to sales | 0 | 0 | 0 | 0 | 0 | |
| Enterprise value over EBITDA | -400.96K | -21.64K | -7.62K | -15.65K | -9.94K | |
| EV to operating cash flow | -713.76K | -27.39K | -10.26K | -18.55K | -11.15K | |
| EV to free cash flow | -713.76K | -27.3K | -9.98K | -18.52K | -11.11K | |
| Earnings yield | 0 | 0 | 0 | 0 | 0 | |
| Free cash flow yield | 0 | 0 | 0 | 0 | 0 | |
| Debt to equity | 0 | 0 | 0 | 0.01 | 0.04 | |
| Debt to assets | 0 | 0 | 0 | 0.01 | 0.03 | |
| Net debt to EBITDA | 0.84 | 6.05 | 1.54 | 1.56 | 1.2 | |
| Current ratio | 4.79 | 27.02 | 7.68 | 7.42 | 5.91 | |
| Interest coverage | 0 | 0 | 0 | 0 | 0 | |
| Income quality | 0.56 | 0.79 | 0.75 | 0.86 | 0.9 | |
| Dividend Yield | 0 | 0 | 0 | 0 | 0 | |
| Payout ratio | -0.26 | 0 | 0 | 0 | 0 | |
| Sales general and administrative to revenue | 0 | 0 | 0 | 0 | 0 | |
| Research and developement to revenue | 0 | 0 | 0 | 0 | 0 | |
| Intangibles to total assets | 0 | 0 | 0 | 0 | 0 | |
| Capex to operating cash flow | 0 | 0 | 0.03 | 0 | 0 | |
| Capex to revenue | 0 | 0 | 0 | 0 | 0 | |
| Capex to depreciation | 0 | -4.15 | -5.45 | -0.44 | -0.97 | |
| Stock based compensation to revenue | 0 | 0 | 0 | 0 | 0 | |
| Graham number | 0.47 | 26.82 | 20.37 | 22.81 | 18.93 | |
| ROIC | -1.35 | -0.17 | -0.75 | -0.67 | -0.87 | |
| Return on tangible assets | -1.07 | -0.16 | -0.62 | -0.58 | -0.75 | |
| Graham Net | 0.07 | 13.45 | 4.92 | 5.57 | 3.82 | |
| Working capital | 2.27M | 195.43M | 121.59M | 159.15M | 132.8M | |
| Tangible asset value | 2.28M | 195.98M | 124M | 162.3M | 136.15M | |
| Net current asset value | 2.27M | 195.43M | 121.13M | 157.4M | 128.13M | |
| Invested capital | 0 | 0 | 0 | 0.01 | 0.04 | |
| Average receivables | 0 | 0 | 0 | 0 | 0 | |
| Average payables | 300.5K | 2.44M | 7.54M | 13.18M | 14.88M | |
| Average inventory | 0 | 0 | 0 | 0 | 0 | |
| Days sales outstanding | 0 | 0 | 0 | 0 | 0 | |
| Days payables outstanding | 0 | 0 | 0 | 0 | 0 | |
| Days of inventory on hand | 0 | 0 | 0 | 0 | 0 | |
| Receivables turnover | 0 | 0 | 0 | 0 | 0 | |
| Payables turnover | 0 | 0 | 0 | 0 | 0 | |
| Inventory turnover | 0 | 0 | 0 | 0 | 0 | |
| ROE | -1.35 | -0.17 | -0.72 | -0.67 | -0.93 | |
| Capex per share | 0 | -0.01 | -0.08 | -0.01 | -0.01 |
Quarterly Fundamentals Overview
Last date of statement is 2021-09-30 for Q3
| Metric | History | 2020-09-30 | 2020-12-31 | 2021-03-31 | 2021-06-30 | 2021-09-30 |
|---|---|---|---|---|---|---|
| 2.02K | 2.02K | 2.02K | 2.02K | 2.02K | ||
| Revenue per share | 0 | 0 | 0 | 0 | 0 | |
| Net income per share | -0.93 | 0 | -0.9 | -0.59 | -0.63 | |
| Operating cash flow per share | -0.77 | 0 | -0.67 | -0.61 | -0.4 | |
| Free cash flow per share | -0.77 | 0 | -0.67 | -0.61 | -0.4 | |
| Cash per share | 5.74 | 0 | 3.56 | 2.9 | 2.51 | |
| Book value per share | 5.05 | 0 | 2.82 | 2.23 | 1.88 | |
| Tangible book value per share | 5.05 | 0 | 2.82 | 2.23 | 1.88 | |
| Share holders equity per share | 5.05 | 0 | 2.82 | 2.23 | 1.88 | |
| Interest debt per share | 0.16 | 0 | 0.14 | 0.13 | 0.13 | |
| Market cap | 881.59B | 1261922B | 255.82B | 264.7B | 220.71B | |
| Enterprise value | 881.41B | 1261921.84B | 255.69B | 264.59B | 220.62B | |
| P/E ratio | -7.23K | -9.77M | -1.89K | -2.94K | -2.3K | |
| Price to sales ratio | 0 | 0 | 0 | 0 | 0 | |
| POCF ratio | -35.05K | -40.06M | -10.27K | -11.49K | -14.62K | |
| PFCF ratio | -34.78K | -40.04M | -10.26K | -11.49K | -14.62K | |
| P/B Ratio | 5.32K | 9.27M | 2.43K | 3.13K | 3.09K | |
| PTB ratio | 5.32K | 9.27M | 2.43K | 3.13K | 3.09K | |
| EV to sales | 0 | 0 | 0 | 0 | 0 | |
| Enterprise value over EBITDA | -28.92K | -39.06M | -7.6K | -12.6K | 36.85K | |
| EV to operating cash flow | -35.04K | -40.06M | -10.26K | -11.49K | -14.61K | |
| EV to free cash flow | -34.77K | -40.04M | -10.26K | -11.49K | -14.61K | |
| Earnings yield | 0 | 0 | 0 | 0 | 0 | |
| Free cash flow yield | 0 | 0 | 0 | 0 | 0 | |
| Debt to equity | 0.03 | 0.04 | 0.05 | 0.06 | 0.07 | |
| Debt to assets | 0.03 | 0.03 | 0.04 | 0.04 | 0.05 | |
| Net debt to EBITDA | 6 | 4.7 | 3.8 | 5 | -15.06 | |
| Current ratio | 6.68 | 5.91 | 4.11 | 3.78 | 3.29 | |
| Interest coverage | 0 | 0 | 0 | 0 | 0 | |
| Income quality | 0.83 | 0.98 | 0.74 | 1.05 | 1.08 | |
| Dividend Yield | 0 | 0 | 0 | 0 | 0 | |
| Payout ratio | 0 | 0 | 0 | 0 | 0 | |
| Sales general and administrative to revenue | 0 | 0 | 0 | 0 | 0 | |
| Research and developement to revenue | 0 | 0 | 0 | 0 | 0 | |
| Intangibles to total assets | 0 | 0 | 0 | 0 | 0 | |
| Capex to operating cash flow | 0.01 | 0 | 0 | 0 | 0 | |
| Capex to revenue | 0 | 0 | 0 | 0 | 0 | |
| Capex to depreciation | -1.15 | -0.13 | -0.17 | -0.04 | 0 | |
| Stock based compensation to revenue | 0 | 0 | 0 | 0 | 0 | |
| Graham number | 10.27 | 0.01 | 7.56 | 5.46 | 5.17 | |
| ROIC | -0.17 | -0.22 | -0.29 | -0.24 | 0.12 | |
| Return on tangible assets | -0.15 | -0.19 | -0.24 | -0.19 | -0.23 | |
| Graham Net | 4.72 | 0 | 2.56 | 2.01 | 1.6 | |
| Working capital | 162.19M | 132.8M | 103.01M | 82.42M | 69.29M | |
| Tangible asset value | 165.6M | 136.15M | 105.3M | 84.63M | 71.37M | |
| Net current asset value | 157.34M | 128.13M | 98.53M | 78.12M | 65.18M | |
| Invested capital | 0.03 | 0.04 | 0.05 | 0.06 | 0.07 | |
| Average receivables | 0 | 0 | 0 | 0 | 0 | |
| Average payables | 14.55M | 14.1M | 14.71M | 14.19M | 12.39M | |
| Average inventory | 0 | 0 | 0 | 0 | 0 | |
| Days sales outstanding | 0 | 0 | 0 | 0 | 0 | |
| Days payables outstanding | 0 | 0 | 0 | 0 | 0 | |
| Days of inventory on hand | 0 | 0 | 0 | 0 | 0 | |
| Receivables turnover | 0 | 0 | 0 | 0 | 0 | |
| Payables turnover | 0 | 0 | 0 | 0 | 0 | |
| Inventory turnover | 0 | 0 | 0 | 0 | 0 | |
| ROE | -0.18 | -0.24 | -0.32 | -0.27 | -0.34 | |
| Capex per share | -0.01 | 0 | 0 | 0 | 0 |
ODTC Frequently Asked Questions
What is Odonate Therapeutics, Inc. stock symbol ?
Odonate Therapeutics, Inc. is a US stock , located in New york of Ny and trading under the symbol ODTC
What is Odonate Therapeutics, Inc. stock quote today ?
Odonate Therapeutics, Inc. stock price is $1.5 today.
Is Odonate Therapeutics, Inc. stock public?
Yes, Odonate Therapeutics, Inc. is a publicly traded company.
Company Profile
- Volume Average 2.63K
- Market Capitalization 34.64K
- Employee 137
- CEO Mr. Kevin C. Tang
- Headquarters New York,NY,US
- IPO Date 2017-12-07
-
Website
https://www.odonate.com 
Odonate Therapeutics, Inc., a pharmaceutical company, develops therapeutics for the treatment of cancer. It is developing tesetaxel, an orally administered chemotherapy agent, which is in Phase III clinical study for patients with metastatic breast cancer. The company was founded in 2013 and is based in New York, New York.
